JP Morgan Chase
ALNY icon

JP Morgan Chase’s Alnylam Pharmaceuticals ALNY Stock Holding History

JP Morgan Chase’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.79M Sell
12,000
-28,000
-70% -$9.53M ﹤0.01% 3584
2025
Q4 		$15.9M Buy
40,000
+37,600
+1,567% +$16.6M ﹤0.01% 2266
2025
Q3 		$1.09M Sell
2,400
-3,000
-56% -$1.22M ﹤0.01% 4516
2025
Q2 		$1.76M Buy
5,400
+1,400
+35% +$387K ﹤0.01% 4007
2025
Q1 		$1.08M Buy
4,000
+3,800
+1,900% +$977K ﹤0.01% 4289
2024
Q4 		$47.1K Buy
+200
New +$52.6K ﹤0.01% 6039
2024
Q3 		– Sell
-44,300
Closed -$10.8M – 7398
2024
Q2 		$10.8M Sell
44,300
-56,200
-56% -$8.87M ﹤0.01% 2396
2024
Q1 		$15M Buy
100,500
+37,700
+60% +$6.29M ﹤0.01% 2132
2023
Q4 		$12M Buy
62,800
+22,800
+57% +$3.88M ﹤0.01% 2285
2023
Q3 		$7.08M Sell
40,000
-10,000
-20% -$1.91M ﹤0.01% 2568
2023
Q2 		$9.5M Hold
50,000
– – ﹤0.01% 2329
2023
Q1 		$10M Buy
50,000
+10,000
+25% +$2.1M ﹤0.01% 2281
2022
Q4 		$9.51M Buy
+40,000
New +$8.53M ﹤0.01% 2307
2022
Q3 		– Sell
-11,900
Closed -$1.74M – 6432
2022
Q2 		$1.74M Buy
11,900
+300
+3% +$42.6K ﹤0.01% 3660
2022
Q1 		$1.89M Sell
11,600
-71,700
-86% -$10.9M ﹤0.01% 3802
2021
Q4 		$14.1M Buy
+83,300
New +$15.5M ﹤0.01% 2129
2021
Q3 		– Sell
-35,000
Closed -$5.93M – 6454
2021
Q2 		$5.93M Buy
+35,000
New +$5.13M ﹤0.01% 2911
2020
Q2 		– Sell
-20,000
Closed -$2.18M – 5341
2020
Q1 		$2.18M Buy
+20,000
New +$2.31M ﹤0.01% 2902
2019
Q2 		– Sell
-18,000
Closed -$1.68M – 5751
2019
Q1 		$1.68M Buy
+18,000
New +$1.51M ﹤0.01% 3450
2018
Q4 		– Sell
-30,000
Closed -$2.63M – 5667
2018
Q3 		$2.63M Buy
30,000
+3,000
+11% +$302K ﹤0.01% 3264
2018
Q2 		$2.66M Hold
27,000
– – ﹤0.01% 3180
2018
Q1 		$3.22M Buy
+27,000
New +$3.48M ﹤0.01% 2930

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's ALNY Position: Q1 2026 in Review

JP Morgan Chase increased its Alnylam Pharmaceuticals (ALNY) stake by 34% in Q1 2026, buying an estimated $546M and bringing the position to 6,323,752 shares worth $2B. The position accounts for 0.13% of the portfolio, ranked #162.

JP Morgan Chase first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.07B in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • JP Morgan Chase held 6,323,752 shares of Alnylam Pharmaceuticals worth $2B as of Q1 2026.
  • JP Morgan Chase bought 1,603,753 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $546M.
  • Alnylam Pharmaceuticals made up 0.13% of JP Morgan Chase's portfolio in Q1 2026, its #162 holding.
  • JP Morgan Chase first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Alnylam Pharmaceuticals position peaked at $2.07B in Q3 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.